Immuneering Corporation (IMRX) Q4 2024 Annual Earnings
IMRX·Reported March 20, 2025·Before market open
Diluted EPS came in at $-0.58, missed the $-0.42 consensus by $0.16.
Diluted EPS
$-0.58missed by $0.16
Consensus: $-0.42
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Immuneering Corporation's Q4 2024 earnings report.
Immuneering Corporation (IMRX) reported Q4 2024 earnings on March 20, 2025 before market open.
Immuneering Corporation reported diluted EPS of $-0.58 for Q4 2024.
EPS missed the consensus estimate of $-0.42 by $0.16.
You can read the 10-K periodic report (0001790340-25-000042) directly on SEC EDGAR. The filing index links above go to sec.gov.